PDX Core

PDX核心是WU-PDTC的中心，因为它将负责开发、组织、 用于研究项目的高质量无病原体PDX模型的表征、存储和传播 调查WU-PDTC内外的抗癌药物。PDX核心建立在出色的现有基础上 华盛顿大学医学院(WUSM)的基础设施和专业知识。《人与鼠》 临床和翻译研究所(ICTS)的肿瘤关联评估(Hamlet)PDX核心 而由李博士和菲尔兹领导的实体肿瘤组织银行和注册中心(STTBR)分别有一个经过证明的 从多种癌症生成PDX模型的成功记录以及将这些模型用于 药物测试。在这些计划之间，我们已经生成了超过449个PDX型号，涉及12多个 癌症类型，从最常见的癌症，如乳腺癌、肺癌和结直肠癌，到罕见的癌症，如 肉瘤和淋巴瘤。这些现有车型将成为新的WU-PDTC的一部分，其中约有1000辆 将开发新的PDX型号并将其添加到此集合中。新的PDX型号将进一步增强我们的 有能力支持正在进行的项目，并为罕见癌症类型的研究开辟新的机会。拿走 利用拟议的WU-PDTC和WUSM内强大的蛋白质组学能力，我们将扩大 这些PDX模型的特征包括整个外显子组测序和RNA-Seq，提供了 研究人员更全面地了解突变图谱、分子特征、克隆 结构和模型的异质性，以帮助癌症亚型和靶点选择。此外 WU-PDTC的研究项目，PDX核心收藏中的PDX型号也将与其他PDTC共享 并向授权的非网络调查人员广泛提供。此外，PDX核心将研究 改进PDX模型的取样率、保真度和特性的新方法。庞大的病人基础 而特别强大的机构支持，包括配套资金，将额外确保这些 目标是可以实现的。

The PDX Core is the epicenter of the WU-PDTC as it will be responsible for the development, organization, characterization, storage, and dissemination of high quality pathogen free PDX models for research projects investigating anticancer agents, within and outside of WU-PDTC. The PDX Core builds on outstanding existing infrastructure and expertise at Washington University School of Medicine (WUSM). The Human and Mouse Linked Evaluation of Tumors (HAMLET) PDX Core at the Institute of Clinical and Translational Study (ICTS) and the Solid Tumor Tissue Bank and Registry (STTBR) led by Drs. Li and Fields, respecitvely, have a proven record of success in generating PDX models from a wide variety of cancers and in utilizing these models for drug testing. Between these programs, we have already generated over 449 PDX models across more than 12 cancer types, from the most common cancers, such as breast, lung, and colorectal, to rare cancers, such as sarcomas and lymphomas. These existing models will become part of the new WU-PDTC, where about 1000 new PDX models will be developed and added to this collection. The new PDX models will further enhance our capability to support ongoing projects and open new opportunities for research in rare cancer types. Taking advantage of the strong proteogenomic capability within the proposed WU-PDTC and WUSM, we will expand the characterization of these PDX models to include both whole exome sequencing and RNA-Seq, providing investigators with a more comprehensive picture of the mutational profiles, the molecular signatures, clonal structures, and heterogeneities of the models to help with cancer sub-typing and target selection. Besides research projects at WU-PDTC, PDX models in the PDX Core collection will also be shared with other PDTCs and made broadly available to authorized non-network investigators. Furthermore, the PDX Core will study new approahes to improve the take rate, fidelity, and characterization of PDX models. The large patient base and exceptionally strong institutional backing, including matching funds, will additionally ensure that these goals are achievable.